Drugs / anti-SARS-CoV-2 IgY
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04567810 | Sep → Dec 2020 | COVID-19 | Stanford University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-SARS-CoV-2 IgY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04567810 ↗ |
| Known as | anti-SARS-CoV-2 RBD IgY | “Although initially raised against the 2019 novel coronavirus index strain (2019-nCoV), these anti-SARS-CoV-2 RBD IgY surprisingly had indistinguishable enzyme-linked...” PMID 35720389 ↗ Jun 2022 |
| Modality | Protein / enzyme biologic | “Antibodies from eggs of hens (immunoglobulin Y; IgY)” PMID 35720389 ↗ Jun 2022 |
| Route | Intranasal | “administered intranasally” NCT04567810 ↗ |